Rising Prevalence Of Neurological Disorders To Drive Growth In Implantable Neurostimulation Device Market: Strategic Insights Driving Implantable Neurostimulation Devices Market Momentum in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Implantable Neurostimulation Devices Market Size By 2025?
The market size for implantable neurostimulation devices has seen swift expansion in recent times. The market value is projected to rise from $8.68 billion in 2024 to $9.64 billion in 2025, marking a compound annual growth rate (CAGR) of 11.1%. Factors attributing to this growth during the historical period include an elevated need for non-pharmacological treatment methods, heightened demand for minimally invasive procedures, an increasing elderly population, a broader range of psychiatric disorders, and a rise in the prevalence of chronic illnesses.

How Big Is the Implantable Neurostimulation Devices Market Size Expected to Grow by 2029?
In the coming years, the market size for implantable neurostimulation devices is projected to undergo swift expansion, reaching $14.53 billion by 2029 at a compound annual growth rate (CAGR) of 10.8%. This growth during the forecast period is due to factors such as a higher incidence of neurological disorders, the increasing prevalence of lifestyle diseases, heightened awareness, a rise in spinal cord injury cases as well as growing healthcare spending. The forecast period is also marked by key trends like the use of sensing technology, advancements in neurostimulation technologies, the development of technologically advanced products, the adoption of closed-loop systems, and the integration of wireless technology.

View the full report here:
https://www.thebusinessresearchcompany.com/report/implantable-neurostimulation-devices-global-market-report

Which Key Market Drivers Powering Implantable Neurostimulation Devices Market Expansion and Growth?
The increased frequency of neurological conditions is believed to be a driving force behind the future expansion of the implantable neurostimulation device market. Neurological disorders are afflictions that interfere with the function or structure of the nervous system, leading to a range of symptoms such as seizures, paralysis, and cognitive difficulties. An increase in risk factors like trauma, developmental defects, and high blood pressure have resulted in a higher detection rate of such disorders. Implantable neurostimulation devices, which offset nerve activity and relieve symptoms when other remedies have been ineffective or inadequate, are employed to treat these disorders. For example, the Alzheimer's Association, a non-profit voluntary health organization based in the US, predicted that in 2024, around 6.9 million Americans aged 65 and above will have Alzheimer's disease, with 73% of them being 75 or older. It is expected that this figure will escalate to 12.7 million by 2050. Consequently, the escalating incidence of neurological disorders will fuel the growth of the implantable neurostimulation device market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19520&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Implantable Neurostimulation Devices Market?
Major players in the implantable neurostimulation devices market are focusing their efforts on creating state-of-the-art products such as spinal cord stimulation (SCS) systems, which are designed to alleviate chronic pain. SCS systems are medical devices that use electric shocks to regulate spinal cord nerve activity and enhance patient quality of life when other treatments have been unsuccessful. Take for example, Abbott, an American medical device company, which announced in December 2022 that it had secured an approval from the U.S. Food and Drug Administration (FDA) for its Eterna spinal cord stimulation (SCS) system. Presently, Eterna SCS is the smallest rechargeable implantable spinal cord stimulator on the market, specifically designed for optimal everyday comfort. It incorporates Abbott's exclusive BurstDR stimulation technology, which replicates the natural firing patterns of the brain for exceptional pain reduction and is favoured by 87% of patients over the standard tingling sensation. With minimal recharge needs, Eterna offers convenience due to its Xtend energy technology, requiring only around five recharges a year. This system is also equipped to support full-body MRI scans with TotalScan technology and can accommodate future technological developments without needing replacement. Additionally, Eterna's integration with a mobile app enables users to monitor battery life and charging status in real time on iPhone devices.

What Are the Emerging Segments in the Implantable Neurostimulation Devices Market?
The implantable neurostimulation devicesmarket covered in this report is segmented -

1) By Type: Spinal Cord Stimulation (SCS), Gastric Electric Stimulation (GES), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS), Vagus Nerve Stimulation (VNS), Other Types
2) By Application: Pain Management, Parkinson's Disease, Urinary And Fecal Incontinence, Epilepsy, Gastroparesis, Other Applications
3) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers

Subsegments:
1) By Spinal Cord Stimulation (SCS): Rechargeable SCS Devices, Non-Rechargeable SCS Devices
2) By Gastric Electric Stimulation (GES): Implantable Gastric Stimulators, Adjustable Gastric Stimulators
3) By Deep Brain Stimulation (DBS): DBS Devices for Movement Disorders, DBS Devices for Psychiatric Disorders
4) By Sacral Nerve Stimulation (SNS): SNS Devices for Urinary Incontinence, SNS Devices for Fecal Incontinence
5) By Vagus Nerve Stimulation (VNS): VNS Devices for Epilepsy, VNS Devices for Depression
6) By Other Types: Peripheral Nerve Stimulation (PNS), Cortical Stimulation Devices, Novel Neurostimulation Technologies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=19520&type=smp

Who Are the Global Leaders in the Implantable Neurostimulation Devices Market?
Major companies operating in the implantable neurostimulation devices market are Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, Dignity Health, St. Jude Medical LLC, LivaNova PLC, Nevro Corp., Axonics Inc., NeuroPace Inc., Bioness Inc., Saluda Medical Pty Ltd., SceneRay Co. Ltd., NeuroMetrix Inc., CURE Epilepsy, Synapse Biomedical Inc., NeuroSigma Inc., Nuvectra Corporation, MicroTransponder Inc., Pain Management NYC, Curonix LLC

Which are the Top Profitable Regional Markets for the Implantable Neurostimulation Devices Industry?
North America was the largest region in the implantable neurostimulation devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the implantable neurostimulation devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19520

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe - +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email: info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.